Drugs / HBc-HBs/AS01B-4
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05276297 | Mar 2022 → Aug 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBc-HBs/AS01B-4 | “2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period.” NCT05276297 ↗ |
| Modality | Vaccine | “AS01B-4-adjuvanted HBc-HBs proteins” NCT05276297 ↗ |
| Route | Intramuscular | “4 doses administered intramuscularly as follows:” NCT05276297 ↗ |